Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

324.23 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19
The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients. 
Via Benzinga
Eli Lilly's Olumiant Becomes First FDA Approved Immunomodulatory Treatment For COVID-19
 
Via Benzinga
7 Biotech Stocks With Key Catalysts for May
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
Via InvestorPlace
This Company Is Reportedly Solving Bedroom Performance Issues Behind Closed Doors
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review
The Nasdaq hit its lowest level since 2020. Apple and Facebook led key earnings. 
Via Investor's Business Daily
Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout
 
Via Benzinga
Here's How Much $1000 Invested In Eli Lilly 10 Years Ago Would Be Worth Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.8% on an annualized basis producing an average annual return of 21.54%. Currently, Eli Lilly has a market capitalization of... 
Via Benzinga
Eli Lilly Whale Trades For April 28
Benzinga's options scanner just detected over 16 options trades for Eli Lilly (NYSE:LLY) summing a total amount of $701,114. At the same time, our algo caught 4 for a total amount of 146,845. 
Via Benzinga
How is it going with the Big Biopharma Earnings Week?
Abbott and JNJ kicked off healthcare earnings last week and the results were just OK. 
Via Talk Markets
Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance
 
Via Benzinga
Peering Into Eli Lilly and Company's Recent Short Interest
Eli Lilly and Company's (NYSE:LLY) short percent of float has fallen 12.05% since its last report. The company recently reported that it has 5.79 million shares sold short, which... 
Via Benzinga
A Tale of Tangles Chapter Three: The Desert Expanse
Source: © Sergey Pesterev / Wikimedia Commons / CC BY-SA 4.0 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Eli Lilly: Q1 Earnings Insights
Eli Lilly (NYSE:LLY) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:25 AM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Eli Lilly Rallies On First-Quarter Beat And As Obesity Drug Cuts 20% Body Weight
Eli Lilly easily topped first-quarter estimates and raised its sales outlook. It also reported promising results in obesity treatment. 
Via Investor's Business Daily
Earnings Preview For Eli Lilly
Eli Lilly (NYSE:LLY) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Eli Lilly will... 
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
How To Attend Eli Lilly Q1 2022 Earnings Conference Call
Eli Lilly (NYSE:LLY) will host a conference call at 09:00 AM ET on April 28, 2022, to discuss Q1 2022 earnings results. How to Attend Eli Lilly (LLY) Conference Call Follow this link to access the live... 
Via Benzinga
Lilly Looks Like A Winner
In February, LLY reported strong earnings, but those numbers were slightly below estimates. However, LLY has been very strong on the earnings front, with recent quarterly and annual EPS growth in the... 
Via Talk Markets
3 Mutual Funds to Buy for April
These are the best mutual funds to buy now. FSDIX, HGITX and VEVFX can make great investments in future months. 
Via InvestorPlace
Will AbbVie And These Two Other Drug Stocks Reinvigorate — Or Incinerate?
The first-quarter earnings season kicks off at a challenging time for AbbVie. 
Via Investor's Business Daily
Eli Lilly Reveals More Phase 3 Data From Lebrikizumab Trial In Atopic Dermatitis
Eli Lilly And Co (NYSE: LLY)  
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
Raytheon, Shell Lead Five Stocks Setting Up, Breaking Out From Strong Sectors
Raytheon and Shell are just below buy points. They have good company. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
How Medicare 'Snuffed Out' Hope For Biogen's Controversial Alzheimer's Drug
Only Medicare patients enrolled in specific studies will receive reimbursement. 
Via Investor's Business Daily
Why Is Biogen (BIIB) Stock in the Spotlight Today?
Medicare's decision not to cover the cost of the drug maker's expensive Alzheimer's drug is hitting the company's stock price today. 
Via InvestorPlace
Executives Sell Over $44M Of 4 Stocks
Although gold futures traded slightly lower on Friday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s... 
Via Benzinga
Stocks That Hit 52-Week Highs On Thursday
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.